Cargando…
p53 sensitizes chemoresistant non-small cell lung cancer via elevation of reactive oxygen species and suppression of EGFR/PI3K/AKT signaling
BACKGROUND: Non-small cell lung cancer (NSCLC) is the leading cause of cancer deaths primarily due to chemoresistance. Somatic mutation of TP53 (36%) and epidermal growth factor receptor (EGFR; > 30%) are major contributors to cisplatin (CDDP) resistance. Substantial evidence suggests the elevate...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6642601/ https://www.ncbi.nlm.nih.gov/pubmed/31360122 http://dx.doi.org/10.1186/s12935-019-0910-2 |
_version_ | 1783437010320490496 |
---|---|
author | Zhang, Yize Han, Chae Young Duan, Fu Gang Fan, Xing-Xing Yao, Xiao-Jun Parks, Robin J. Tang, Yi-Jun Wang, Mei-Fang Liu, Liang Tsang, Benjamin K. Leung, Elaine Lai-Han |
author_facet | Zhang, Yize Han, Chae Young Duan, Fu Gang Fan, Xing-Xing Yao, Xiao-Jun Parks, Robin J. Tang, Yi-Jun Wang, Mei-Fang Liu, Liang Tsang, Benjamin K. Leung, Elaine Lai-Han |
author_sort | Zhang, Yize |
collection | PubMed |
description | BACKGROUND: Non-small cell lung cancer (NSCLC) is the leading cause of cancer deaths primarily due to chemoresistance. Somatic mutation of TP53 (36%) and epidermal growth factor receptor (EGFR; > 30%) are major contributors to cisplatin (CDDP) resistance. Substantial evidence suggests the elevated levels of reactive oxygen species (ROS) is a key determinant in cancer. The elevated ROS can affect the cellular responses to chemotherapeutic treatments. Although the role of EGFR in PI3K/Akt signaling cascade in NSCLC is extensively studied, the molecular link between EGFR and p53 and the role of ROS in pathogenesis of NSCLC are limitedly addressed. In this study, we investigated the role of p53 in regulation of ROS production and EGFR signaling, and the chemosensitivity of NSCLC. METHODS: In multiple NSCLC cell lines with varied p53 and EGFR status, we compared and examined the protein contents involved in EGFR-Akt-P53 signaling loop (EGFR, P-EGFR, Akt, P-Akt, p53, P-p53) by Western blot. Apoptosis was determined based on nuclear morphological assessment using Hoechst 33258 staining. Cellular ROS levels were measured by dichlorofluorescin diacetate (DCFDA) staining followed by flow cytometry analysis. RESULTS: We have demonstrated for the first time that activation of p53 sensitizes chemoresistant NSCLC cells to CDDP by down-regulating EGFR signaling pathway and promoting intracellular ROS production. Likewise, blocking EGFR/PI3K/AKT signaling with PI3K inhibitor elicited a similar response. Our findings suggest that CDDP-induced apoptosis in chemosensitive NSCLC cells involves p53 activation, leading to suppressed EGFR signaling and ROS production. In contrast, in chemoresistant NSCLC, activated Akt promotes EGFR signaling by the positive feedback loop and suppresses CDDP-induced ROS production and apoptosis. CONCLUSION: Collectively, our study reveals that the interaction of the p53 and Akt feedback loops determine the fate of NSCLC cells and their CDDP sensitivity. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12935-019-0910-2) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6642601 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-66426012019-07-29 p53 sensitizes chemoresistant non-small cell lung cancer via elevation of reactive oxygen species and suppression of EGFR/PI3K/AKT signaling Zhang, Yize Han, Chae Young Duan, Fu Gang Fan, Xing-Xing Yao, Xiao-Jun Parks, Robin J. Tang, Yi-Jun Wang, Mei-Fang Liu, Liang Tsang, Benjamin K. Leung, Elaine Lai-Han Cancer Cell Int Primary Research BACKGROUND: Non-small cell lung cancer (NSCLC) is the leading cause of cancer deaths primarily due to chemoresistance. Somatic mutation of TP53 (36%) and epidermal growth factor receptor (EGFR; > 30%) are major contributors to cisplatin (CDDP) resistance. Substantial evidence suggests the elevated levels of reactive oxygen species (ROS) is a key determinant in cancer. The elevated ROS can affect the cellular responses to chemotherapeutic treatments. Although the role of EGFR in PI3K/Akt signaling cascade in NSCLC is extensively studied, the molecular link between EGFR and p53 and the role of ROS in pathogenesis of NSCLC are limitedly addressed. In this study, we investigated the role of p53 in regulation of ROS production and EGFR signaling, and the chemosensitivity of NSCLC. METHODS: In multiple NSCLC cell lines with varied p53 and EGFR status, we compared and examined the protein contents involved in EGFR-Akt-P53 signaling loop (EGFR, P-EGFR, Akt, P-Akt, p53, P-p53) by Western blot. Apoptosis was determined based on nuclear morphological assessment using Hoechst 33258 staining. Cellular ROS levels were measured by dichlorofluorescin diacetate (DCFDA) staining followed by flow cytometry analysis. RESULTS: We have demonstrated for the first time that activation of p53 sensitizes chemoresistant NSCLC cells to CDDP by down-regulating EGFR signaling pathway and promoting intracellular ROS production. Likewise, blocking EGFR/PI3K/AKT signaling with PI3K inhibitor elicited a similar response. Our findings suggest that CDDP-induced apoptosis in chemosensitive NSCLC cells involves p53 activation, leading to suppressed EGFR signaling and ROS production. In contrast, in chemoresistant NSCLC, activated Akt promotes EGFR signaling by the positive feedback loop and suppresses CDDP-induced ROS production and apoptosis. CONCLUSION: Collectively, our study reveals that the interaction of the p53 and Akt feedback loops determine the fate of NSCLC cells and their CDDP sensitivity. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12935-019-0910-2) contains supplementary material, which is available to authorized users. BioMed Central 2019-07-19 /pmc/articles/PMC6642601/ /pubmed/31360122 http://dx.doi.org/10.1186/s12935-019-0910-2 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Primary Research Zhang, Yize Han, Chae Young Duan, Fu Gang Fan, Xing-Xing Yao, Xiao-Jun Parks, Robin J. Tang, Yi-Jun Wang, Mei-Fang Liu, Liang Tsang, Benjamin K. Leung, Elaine Lai-Han p53 sensitizes chemoresistant non-small cell lung cancer via elevation of reactive oxygen species and suppression of EGFR/PI3K/AKT signaling |
title | p53 sensitizes chemoresistant non-small cell lung cancer via elevation of reactive oxygen species and suppression of EGFR/PI3K/AKT signaling |
title_full | p53 sensitizes chemoresistant non-small cell lung cancer via elevation of reactive oxygen species and suppression of EGFR/PI3K/AKT signaling |
title_fullStr | p53 sensitizes chemoresistant non-small cell lung cancer via elevation of reactive oxygen species and suppression of EGFR/PI3K/AKT signaling |
title_full_unstemmed | p53 sensitizes chemoresistant non-small cell lung cancer via elevation of reactive oxygen species and suppression of EGFR/PI3K/AKT signaling |
title_short | p53 sensitizes chemoresistant non-small cell lung cancer via elevation of reactive oxygen species and suppression of EGFR/PI3K/AKT signaling |
title_sort | p53 sensitizes chemoresistant non-small cell lung cancer via elevation of reactive oxygen species and suppression of egfr/pi3k/akt signaling |
topic | Primary Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6642601/ https://www.ncbi.nlm.nih.gov/pubmed/31360122 http://dx.doi.org/10.1186/s12935-019-0910-2 |
work_keys_str_mv | AT zhangyize p53sensitizeschemoresistantnonsmallcelllungcancerviaelevationofreactiveoxygenspeciesandsuppressionofegfrpi3kaktsignaling AT hanchaeyoung p53sensitizeschemoresistantnonsmallcelllungcancerviaelevationofreactiveoxygenspeciesandsuppressionofegfrpi3kaktsignaling AT duanfugang p53sensitizeschemoresistantnonsmallcelllungcancerviaelevationofreactiveoxygenspeciesandsuppressionofegfrpi3kaktsignaling AT fanxingxing p53sensitizeschemoresistantnonsmallcelllungcancerviaelevationofreactiveoxygenspeciesandsuppressionofegfrpi3kaktsignaling AT yaoxiaojun p53sensitizeschemoresistantnonsmallcelllungcancerviaelevationofreactiveoxygenspeciesandsuppressionofegfrpi3kaktsignaling AT parksrobinj p53sensitizeschemoresistantnonsmallcelllungcancerviaelevationofreactiveoxygenspeciesandsuppressionofegfrpi3kaktsignaling AT tangyijun p53sensitizeschemoresistantnonsmallcelllungcancerviaelevationofreactiveoxygenspeciesandsuppressionofegfrpi3kaktsignaling AT wangmeifang p53sensitizeschemoresistantnonsmallcelllungcancerviaelevationofreactiveoxygenspeciesandsuppressionofegfrpi3kaktsignaling AT liuliang p53sensitizeschemoresistantnonsmallcelllungcancerviaelevationofreactiveoxygenspeciesandsuppressionofegfrpi3kaktsignaling AT tsangbenjamink p53sensitizeschemoresistantnonsmallcelllungcancerviaelevationofreactiveoxygenspeciesandsuppressionofegfrpi3kaktsignaling AT leungelainelaihan p53sensitizeschemoresistantnonsmallcelllungcancerviaelevationofreactiveoxygenspeciesandsuppressionofegfrpi3kaktsignaling |